A comparative study of the efficacy of topical metformin cream versus placebo in the treatment of melisma

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121104011363N3

Enrollment

Registered

2019-01-14

Start date

2017-08-23

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma. Chloasma

Interventions

Intervention 1: Intervention group: The 15% metformin cream was used twice a day for three months. Intervention 2: Control group: Placebo was used twice a day for three months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with melasma referred to Dermatology Clinic of Ahvaz Imam Khomeini Hospital

Exclusion criteria

Exclusion criteria: Pregnancy Breastfeeding Patients receiving hormone therapy Atrophy and telangiectasia in the place of melasma Use of topical treatment for melasma in the last 3 months History of drug sensitivity GFR less than 30

Design outcomes

Primary

Measure	Time frame
Improvement of MASI score. Timepoint: At the end of every month and 3 months after improvement. Method of measurement: MASI score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGhazal Namdari

Ahvaz University of Medical Sciences

namdari.ghazal@gmail.com+98 61 3587 4366

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026